The economic impact of introducing HIV/AIDS guideline into Colombian National Drug Formulary. Cost-effectiveness analysis

Abstract

10%), Thirteen (13%) and Eleven (11%), P = ns] respectively; new opportunistic infections [Four (4%), Seven (7%), and Three (3%), P = ns] respectively; average CD4 increment by 30% [Eighty (80%), Seventy six (76%), and Eighty three (83%), P = ns] respectively and death [Six (6%), Five (5%), and Four (4%), P = ns] respectively. However, adverse drug side effect occurs more frequently in Group 1 and 2 than in Group 3 [Eighteen (18%) and Twenty (20%) versus Three (3%), P = 0.03] respectively, which more frequently resulted poor adherence in Group 1 and 2 than Group 3 [Seventeen (17%) and Sixteen (16%) versus Three (3%), P = 0.05] respectively. Conclusion:This manuscript shows that in a retrospective review of HIV patients who are in different Antiretroviral drug combination regimens attending follow ups at GUH, the clinical and immunological responses for the different ART regimens are similar and comparable however it depicts differences in areas of drug side effects and adherence problems. Therefore different first line ART drug combinations selection in resource poor countries can be guided by drugs side effect and adherence issues.